NICE wants details on Soliris' development cost

The U.K.'s NICE requested information on the development costs for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) to treat atypical hemolytic uremic syndrome (aHUS), as well as an explanation of how those costs related to Alexion's proposed price for Soliris for the indication. In complement 5 (C5) for aHUS pending a decision from NICE. Soliris is also approved for paroxysmal nocturnal hemoglobinuria (PNH); NHS has covered Soliris for the indication since 2009 (see BioCentury Extra, Sept. 12, 2013). ...